# Safety and Biomarker Study of EPI-589 in Participants With Amyotrophic Lateral Sclerosis (ALS)

> **NCT02460679** · PHASE2 · COMPLETED · sponsor: **PTC Therapeutics** · enrollment: 19 (actual)

## Conditions studied

- Amyotrophic Lateral Sclerosis

## Interventions

- **DRUG:** EPI-589

## Key facts

- **NCT ID:** NCT02460679
- **Lead sponsor:** PTC Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01-14
- **Primary completion:** 2018-02-23
- **Final completion:** 2018-02-23
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2020-10-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02460679

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02460679, "Safety and Biomarker Study of EPI-589 in Participants With Amyotrophic Lateral Sclerosis (ALS)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02460679. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*